NDT Pharmaceuticals, Inc. engages in the business of developing nutraceutical and pharmaceutical products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2006-12-14. The firm has acquired all rights under a Sponsored Research Agreement with the University of Pennsylvania, including rights to use the University's Nanoscale Particle Complex (NPC) technology. The intellectual property includes an applicable biotechnology asset base, including the Nanoscale Particle Complex (NPC) technology, which represents phospholipid-based nano-encapsulation delivery systems that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth. Encapsulated actives are protected from destruction in the highly acidic environment of the stomach until they reach the small intestine. The NPC technology also incorporates a potent active ingredient that stimulates the repair of damaged cell tissue branded by the Company as Cell Armor.
NDTP stock price ended at $1.07 on 火曜日, after dropping 6.96%
On the latest trading day Jan 20, 2026, the stock price of NDTP fell by 6.96%, dropping from $1.05 to $1.07. During the session, the stock saw a volatility of 8.91%, with prices oscillating between a daily low of $1.01 and a high of $1.10. On the latest trading day, the trading volume for NDTP decreased by 6.6K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 3.8K shares were traded, with a market value of approximately $171.2M.